Format

Send to

Choose Destination
Bone Marrow Transplant. 2016 Jun;51(6):786-92. doi: 10.1038/bmt.2016.20. Epub 2016 Feb 22.

Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually.

Author information

1
EBMT Activity Survey Office, Division of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland.
2
Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Frankfurt, Goethe-Universität, Frankfurt am Main, Germany.
3
Università Vita-Salute San Raffaele, Milan, Italy.
4
Paediatric Haematology Oncology, Policlinico G.B. Rossi, Verona, Italy.
5
Medizinische Klinik V, University of Heidelberg, Heidelberg, Germany.
6
Hematology Department, Institut Català d'Oncologia, Hospital Duran I Reynals, Barcelona, Spain.
7
Hematology Unit, G.Gaslini Children's Institute, Genova, Italy.
8
Department of Haematology, University Medical Centre, Utrecht, The Netherlands.
9
Service de Médecine Interne, Maladies Autoimmunes et Pathologie Vasculaire, Hôpital St Louis, Paris, France.
10
Paediatric Team Children's BMT Unit, Great North Children's Hospital, Royal Victoria Infirmary, Newcastle University, Newcastle-Upon-Tyne, UK.
11
Department of Stem cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.
12
Hematology and BMT Unit, Cremona, Italy.
13
Chaim Sheba Medical Center, Tel-Hashomer, Israel.
14
Department of Hematology, Hôpital Saint Antoine, Paris, France.

Abstract

A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers in 47 countries to the 2014 survey. Trends include: continued growth in transplant activity, more so in Eastern European countries than in the west; a continued increase in the use of haploidentical family donors (by 25%) and slower growth for unrelated donor HSCT. The use of cord blood as a stem cell source has decreased again in 2014. Main indications for HSCT were leukemias: 11 853 (33%; 96% allogeneic); lymphoid neoplasias; 20 802 (57%; 11% allogeneic); solid tumors; 1458 (4%; 3% allogeneic) and non-malignant disorders; 2203 (6%; 88% allogeneic). Changes in transplant activity include more allogeneic HSCT for AML in CR1, myeloproliferative neoplasm (MPN) and aplastic anemia and decreasing use in CLL; and more autologous HSCT for plasma cell disorders and in particular for amyloidosis. In addition, data on numbers of teams doing alternative donor transplants, allogeneic after autologous HSCT, autologous cord blood transplants are presented.

PMID:
26901709
PMCID:
PMC4895175
DOI:
10.1038/bmt.2016.20
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center